News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Natera Expands Panorama™ Non-Invasive Prenatal Test To Screen For Clinically Significant Microdeletions


2/5/2014 9:08:59 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN CARLOS, Calif.--(BUSINESS WIRE)--Natera, a leading innovator in prenatal genetic testing, today announced the expansion of the Panorama™ non-invasive prenatal test (NIPT) to screen for five clinically relevant microdeletion syndromes. The expanded test will become available on March 1, 2014. Microdeletions are tiny missing pieces of DNA at the sub-chromosomal level, which can have serious health implications depending on the location of the deletion. Beginning on March 1, screening for 22q11.2 deletion syndrome (also known as DiGeorge syndrome) will become standard on Panorama’s prenatal panel, which already includes screening for trisomy 21 (Down syndrome), trisomy 18, trisomy 13, triploidy, and sex chromosome aneuploidies. Expecting parents will have the additional option to screen for 1p36 deletion, Angelman, Cri-du-chat, and Prader-Willi syndromes.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
Natera
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES